Paysign Q4 Earnings Call Highlights: Revenue Up 40.5%, Net Income Increases 98%, Adjusted EBITDA Surges 107%.

Paysign reported Q4 and full-year 2025 results with revenue up 40.5% to $82.0 million, net income rising 98% to $7.6 million, and adjusted EBITDA increasing 107% to $19.9 million. The company's patient affordability platform saw 168% annual revenue growth, with processed claims up approximately 79%. Paysign added 55 programs during the year and now has active programs with six of the top 10 U.S. pharmaceutical manufacturers.